Heart failure & cardiomyopathies
Effects of angiotensin-neprilysin inhibition in women vs men: Insights from PARAGLIDE-HF
Authors' conclusion
In patients with mildly reduced or preserved EF >40% and a recent worsening HF event, the efficacy, safety and tolerability of sac/val vs valsartan were similar in both women and men, suggesting consistent effects across appropriately selected patients regardless of sex.
Study context
- Population
- Patients with mildly reduced or preserved EF >40% and a recent worsening HF event; women vs men242 women · 224 men
- Comparison
- Sacubitril/valsartan vs valsartan, by sex
- Primary endpoint
- Time-averaged proportional change in NT-proBNP from baseline
- Follow-up
- Weeks 4 and 8
Methodological detailsprespecified subgroup analysis
- Prespecified subgroup analysis
Primary result
As reported in the abstract
Time-averaged NT-proBNP reduction, by sex
Ratio of change
0.86
95% CI 0.69–1.070
women
Ratio of change
0.84
95% CI 0.67–1.05
men
Secondary outcomes
| Outcome | Ratio of change (95% CI) |
|---|---|
| Time-averaged NT-proBNP reduction, overall population | 0.85 (0.73–0.999) |
Secondary hierarchical endpoint, by sex
- Favoured sac/val over valsartan in both women and men but not statistically significant
Original publication
Effects of angiotensin-neprilysin inhibition in women vs men: Insights from PARAGLIDE-HF. Am Heart J. Published 31 March 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →